Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Solid Tumors Treatment Market Cost Analysis, Strategy And Growth Factor Report By 2026

Author: Satish Sraje
by Satish Sraje
Posted: May 25, 2019

A solid tumor is an abnormal mass or lump of tissues without liquid or cysts. It is not necessary that tumor should always be cancerous. On the basis tumor nature, it can be classified as the malignant tumor (cancerous) and the benign tumor (non-cancerous). Based on the cell type, tumors can be classified as carcinomas, sarcomas, and lymphomas. The Solid tumors might occur in several places such as muscle, bone, and organs. Treatments for solid tumors include prevention of tumor and combination of surgery, chemotherapy, and radiation therapy. However, new forms of treatment are emerging in the market.

Emerging trend of Biosimilars therapy is expected to propel the growth of solid tumors treatment marketAccording to data published in International Journal of Pharma Sciences and Research (IJPSR) in 2011, there were around 9 million deaths due to cancer. In 2015, 11.4 million people are expected to die in 2030, among this prevalence of cancer maximum is due to solid tumors. Growing prevalence of solid tumors is the major driving factor for the growth of solid tumors treatment market. Additionally, some other factors fuelling the growth of solid tumors treatment market include unmet demand for cancer treatment and rising investment in the research and development of cancer drugs. However, increase in the volume of generic therapeutic products, the high cost of cancer therapy, and growing drug patent cliff are some of the restraints that might hinder the growth of solid tumors treatment market. Moreover, the emerging trend of biosimilars is contributing to the growth of solid tumors treatment market due to their low cost and their similarity to originator compound. For instance, some of the biologics available for solid tumors treatment includes Herceptin, MabThera, Avastin, and Erbitux. The advantages of this biosimilars to overcome the limitations of generic drugs in the treatments is expected to propel the growth of solid tumors treatments market.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/793

Chemotherapy segment holds the maximum share in solid tumor treatment market due to its efficacy by combining with some other therapies to treat solid tumors.The global solid tumors treatment market is segmented by therapy, by application, by the end user, and by region.On the basis of therapy, solid tumors treatment market is segmented into

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Hormone therapy
  • Targeted therapy

Rising incidences of solid tumor cases in North America is the factor contributing to the growth of solid tumor treatment marketRegional segmentation of Solid Tumors Treatment market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Africa, and the Middle East. North America dominates in the solid tumors treatment market due to the presence of well-established healthcare infrastructure, and rise in the number of solid tumor cases.

Advanced drug therapy is expected to help the industry players to sustain in the solid tumors treatment marketKey industry players operating solid tumors treatment market include Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc., Johnson & Johnson Company, Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline Plc., Sanofi, and Baxter International Incorporated. Advancements in the cancer therapy such as nanomedicines used for the treatment of cancer might help the industry players to provide effective patient care in the solid tumors treatment. Whereas, stringent regulatory policies for drug manufacturing may restrain the growth of the market. For instance, by regulations provided by the Indian government in late 2012, there are cap prices of 348 drugs on Essential Drug List (EDL), and drug manufacturers need to keep the cost of their drugs below the ceiling price.

Click to read more on Solid Tumors Treatment Market

About Coherent Market Insights:Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

About the Author

Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Comment 
Pictures
Author: Satish Sraje

Satish Sraje

Member since: Nov 01, 2018
Published articles: 132

Related Articles